A better understanding of the genetic etiology of pulmonary arterial hypertension and its molecular variants is needed to develop better therapies for the disease, which has no agents available that can reverse or halt it.
Pulmonary arterial hypertension (PAH) has remained a fatal disease with no pharmacological agents available to reverse or halt the disease. As there is no cure, there is an unmet need to understand the genetic etiology of PAH and molecular variants in order to develop better novel therapies.
A study published in The Application of Clinical Genetics identifies potential mutations that are responsible for PAH.
“…A number of potentially causative mutations in genes primarily related to PAH as well as genetic and epigenetic modifiers of disease expression have been discovered via advanced genetic and genomic techniques including but not limited to conventional linkage analysis and next-generation sequencing technologies,” the authors explained.
In familial cases of PAH, not all individuals at risk are affected, and women are preferentially affected in an approximate 2:1 ratio. While 6% of PAH cases are heritable PAH (HPAH), this may be an underestimate, as cases of HPAH may be misclassified as idiopathic PAH (IPAH).
In 75% of HPAH and 20% of IPAH cases, mutations in the gene encoding bone morphogenetic protein receptor type 2 (BMPR2) may be responsible. Compared with patients without the mutation, patients with PAH who have the BMPR2 mutation are not only diagnosed and die 10 years earlier, but they also are less likely to benefit from calcium channel blockers.
BMPR2 mutations are a member of the transforming growth factor-beta (TGF-β) receptor superfamily. The researchers noted that approximately 20% of families with HPAH do not have detectable mutations along this pathway.
“This has led the scientific community to search for additional mutations which may contribute to PAH pathobiology,” they explained. Other genes include:
Targeting molecular pathways that may contribute to PAH could provide new approaches to treat the disease. The 6th World Symposium on Pulmonary Hypertension task force recommends genetic screening even though there is no prevention or cure for PAH. However, identifying heritable disease could allow for closer monitoring, earlier disease detection, and earlier initiation of therapy.
“As genetic and other types of inherent biologic variations rarely occur in isolation, major advancements can be expected in the next few years in the identification of additional genes as well as genetic and environmental modifiers for PAH,” the authors concluded. “Larger genetic and biomarkers studies, with a close interplay of animal and human approaches will be necessary to better understand the complex genetic networks and events that promote PAH in genetically at-risk subjects.”
Reference
Eroume-A Egom E, Moyou-Somo R, Essame Oyono JL, Kamgang R. Identifying potential mutations responsible for cases of pulmonary arterial hypertension. Appl Clin Genet. 2021;14:113-124. doi:10.2147/TACG.S260755
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More